CD8A and nonpapillary renal cell carcinoma: We present results of a phase II study and multi-omic analysis of advanced stage ccRCC through treatment that sheds light on the determinants of anti-PD-1 response and resistance, and in particular the nature of the CD8+ T cells likely contributing to anti-tumor immunity.